1. Home
  2. Health
  3. Arthritis

Prexige (Lumiracoxib) - COX-2 Selective Inhibitor - Drug Information

Prexige (lumiracoxib) is a COX-2 selective inhibitor medication currently in development by Novartis. Drug information on the COX-2 selective inhibitor Prexige, generic drug name lumiracoxib. Prexige (lumiracoxib) has been approved in the United Kingdom. Prexige (lumiracoxib) is slated for approval in the United States in 2007.
10/03/2007: FDA Deems Arthritis Medicine Prexige "Not Approvable"
Prexige (lumiracoxib), a medicine being developed by Novartis as a once-daily treatment for arthritis patients with osteoarthritic pain, has not been approved by the U.S. Food and Drug Administration (FDA). On September 27, 2007, Novartis received a "not approvable" letter from the FDA.
10/3/2007 - Prexige Withdrawn in Canada / USA Does Not Approve Prexige
Australia and Canada have withdrawn Prexige from the market citing liver complications. The U.S. has decided not to approve Prexige.
What Are COX-2 Inhibitors?
A brief explanation and fast facts about the COX-2 inhibitors.
Arthritis Drugs: What Are My Options?
Medications have long been considered "traditional" treatment. Since individual response to a specific medication can vary and because possible side effects are also a factor, finding the most effective medication or combination of medications can be a more difficult process than one would expect.

Explore Arthritis

More from About.com

  1. Home
  2. Health
  3. Arthritis
  4. Arthritis Medications
  5. A - Z: COX-2 Inhibitors
  6. Prexige (Lumiracoxib)

©2008 About.com, a part of The New York Times Company.

All rights reserved.